Murine models of systemic lupus erythematosus.
Perry D, Sang A, Yin Y, Zheng YY, Morel L. · 2011
Read Murine models of systemic lupus erythematosus. by Perry D, Sang A, Yin Y, Zheng YY, Morel L. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3042628.txt.
Introduction
Perry, Sang, Yin, Zheng, and Morel reviewed in 2011 the mouse models that stand in for human lupus, an autoimmune disease in which the body attacks its own tissues. Mice that develop a lupus like illness on their own have revealed many gene regions that raise risk, and several candidate genes inside them. Other mice get the illness only after a trigger, which highlights environmental roles.
Together the models have clarified which immune cells drive the disease and how it starts and worsens. They also serve as test beds for possible lupus drugs before human trials. Because the human disease is so varied, the authors stress matching each targeted drug to what a model can actually show. Lessons from these mice keep shaping the search for safer, more precise treatments.
Catalog record
| CREATOR | Perry D, Sang A, Yin Y, Zheng YY, Morel L. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Murine Models of Systemic Lupus Erythematosus By Daniel Perry, Allison Sang, Yiming Yin, Ying-Yi Zheng, Laurence Morel Published in: Journal of Biomedicine and Biotechnology DOI: 10.1155/2011/271694 ABSTRACT Abstract Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disorder. The study of diverse mouse models of lupus has provided clues to the etiology of SLE. Spontaneous mouse models of lupus have led to identification of numerous susceptibility loci from which several candidate genes have emerged. Meanwhile, induced models of lupus have provided insight into the role of environmental factors in lupus pathogenesis as well as provided a better understanding of cellular mechanisms involved in the onset and progression of disease. The SLE-like phenotypes present in these models have also served to screen numerous potential SLE therapies. Due to the complex nature of SLE, it is necessary to understand the effect specific targeted therapies have on immune homeostasis. Furthermore, knowledge gained from mouse models will provide novel therapy targets for the treatment of SLE. 1. INTRODUCTION The etiology of the autoimmune disease systemic lupus erythematosus (SLE) is considered to be a combination of multiple genetic and environmental factors whose amalgamation breaches the threshold of immune tolerance. SLE is, therefore, a complex multigenic disorder. The causative genetic factors of such disorders are believed to be allelic variants with minor functional contributions to the disease state and, individually, are not sufficient to cause overt disease. However, the combination of several of these susceptibility loci can lead to epistatic interactions that greatly enhance the overall contribution by each locus, whereby protective mechanisms are overcome and pathogenesis ensues. Hence, the capacity to tailor SLE treatments could be greatly enhanced upon the identification of the genetic variants capable of inducing autoimmunity and how their involvement can magnify SLE. Indeed, concerted efforts in human studies and mouse models have been made in that direction. The recent annotation of millions of single nucleotide polymorphisms (SNPs) in the human genome and the inception of high-throughput genotyping technologies has enabled the use of genome-wide association studies (GWAS) for this purpose. To date, SLE susceptibility has been associated to dozens of genes by GWAS [1]. While these associations offer important new insights into SLE etiology, there are logistical limitations to GWAS. Extremely large sample sets are required to achieve significant associations and extrinsic factors such as ethnicity, clinical history, and lifestyle must be considered in choosing these sets. Further, GWAS are capable of identifying genomic associations but do not characterize the function that an allelic variation confers. For this, other methods are required. There are numerous murine models that have long been employed in an effort to understand the cellular and genetic requirements for SLE induction. The classic models of spontaneous lupus include the F1 hybrid between the New Zealand Black (NZB) and New Zealand White (NZW) strains (NZB/W F1) and its derivatives, the MRL/lpr, and BXSB/Yaa strains whereas induced models include the pristane-induced model and the chronic graft-versus-host-disease models (cGVHD). All of these models portray their own iterations of lupus-like diseases with a subset of symptoms akin to those observed in human SLE, namely, autoantibody production, lymphoid activation and hyperplasia, and lupus nephritis. In addition to spontaneous and induced lupus models, there is a plethora of genetically modified mouse models that goes beyond the scope of this paper (reviewed in [2]). Undoubtedly, genetically modified models will be used in the characterization of genes identified by GWAS, and in fact, many of these models already exist [3]. Here, we focus on what has been learned from spontaneous and induced mouse models of SLE and how they can be used to complement the recent advances in human studies. We also highlight how murine models have been used as tools to test therapies. 2. CLASSIC MOUSE MODELS OF SPONTANEOUS LUPUS 2.1. NZB/W F1 The NZB/W F1 is the oldest classical model of lupus generated by the F1 hybrid between the NZB and NZW strains. Both NZB and NZW display limited autoimmunity, while NZB/W F1 hybrids develop severe lupus-like phenotypes comparable to that of lupus patients [4]. These lupus-like phenotypes include lymphadenopathy, splenomegaly, elevated serum antinuclear autoantibodies (ANA) including anti-dsDNA IgG, a majority of which are IgG2a and IgG3, and immune complex-mediated glomerulonephritis (GN) that becomes apparent at 5-6 months of age, leading to kidney failure and death at 10–12 months of age [4]. Unlike SLE patients and the MRL/lpr and BXSB/Yaa mouse models, NZB/W F1 mice lack autoantibodies against RNA-containing complexes. As for SLE patients, disease in the NZB/W F1 strain is strongly biased in favor of females, and this is at least in part due to estrogen levels. Indeed ovariectomy of NZB/W F1 mice not only delayed disease onset but also decreased autoantibody titer. Meanwhile, restoration of estradiol in ovariectomized NZB/W F1 mice reestablished high numbers of DNA-specific B cells, and thereby suggests a pathogenic role of estrogen in lupus [5]. The many contributions of the NZB/W F1 model to our understanding of lupus pathogenesis have been discussed in excellent reviews [2, 4] to which the reader is referred to. 2.1.1. NZM An accidental backcross between NZB/W F1 and NZW followed by brother-sister matings generated 27 different recombinant inbred strains of New Zealand Mixed (NZM) mice among which NZM2328 and NZM2410 are now used as lupus models [6–8]. While both NZM2410 and NZM2328 strains exhibit a highly penetrant version of the NZB/W F1 disease with an earlier onset, NZM2410 differs from NZM2328 with a weaker gender bias [7]. The NZM2328 and 2410 strains share the same autoantibody specificities as NZB/W F1 mice. The homozygosity of the NZM strains and their potential enrichment for lupus susceptibility loci has facilitated genetic analyses, and arguably their greatest contribution has been to the understanding of the genetic basis of this disease. 2.1.2. Identification and Classification of Susceptibility Loci In 1994, Morel et al. reported the first lupus linkage analysis which identified three NZM2410 susceptibility loci, Sle1-3, as being significantly correlated with GN development [7]. The analysis of these loci showed that disease was inherited as a threshold liability, that is, the probability of presenting disease by an individual increases with the number of susceptibility alleles it carries, a concept that has been confirmed in genetic analyses of the other lupus-prone strains. The NZM2410 model was also used to show the existence of NZW-derived suppressive loci, the strongest one, Sles1, being linked to the major histocompatibility complex (MHC) class II locus H-2z [9]. These results showed that the disease outcome for a given genome represents the integration of susceptibility and resistance loci and that lupus susceptible strains carry genomes in which the susceptibility loci outweigh the resistance loci. Resistance (or transgressive) loci have subsequently been identified in other models, including lupus models (e.g., see below Lmb3 in the MRL/lpr strain). The phenotypes contributed by each NZM2410 susceptibility locus have been determined via detailed analysis of the immunological properties of congenic strains carrying the individual loci on a C57BL/6 (B6) genetic background in comparison to B6 mice [10–16]. Briefly, Sle1 mediates the loss of tolerance to nuclear antigens leading to the production of autoreactive B and T cells culminating in the secretion of antinuclear autoantibodies. Sle2 leads to B cell hyperactivity, elevated B-1 cell levels, and polyreactive IgM antibodies. Sle3